Dr. Adil Daud, MD

Medicare patients and services

Medicare patients, 2024

224

Services billed

585

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 5 companies reported 27 payments worth $30,774 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 22 industry-funded studies in 2025, from 9 companies. The companies reported $1,038,315 in research payments for these studies, mostly to the institutions running them.

• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05608291
• A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
  Merck Sharp & Dohme LLC
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06190951
• An openlabel phase 1 study to investigate PF08046031 in adults with advanced melanoma and other solid tumors
  Pfizer Inc.
• Phase Ib/II Trial of anti-PD-1 immunotherapy and Stereotactic Radiation in Patients with Recurrent Glioblastoma
  Merck Sharp & Dohme LLC
• A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06413680
• A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Sta…
  Merck Sharp & Dohme LLC
• A phase 1 study of SGNBB228 in advanced melanoma and other solid tumors
  Pfizer Inc.
• A phase 1AB openlabel master study of PF07799544 as a singleagent and in combination with other targeted agents in participants with advanced solid tumors
  Pfizer Inc.
• A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
  E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06101134

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Tampa

• Mohammed A. Al-jumayli, M.D
• Yasir Alsaraf, MD
• Rand W. Altemose, M.D.
• Claudio Anasetti, MD
• Scott Antonia, MD
• Nelli Bejanyan, M.D.
• Tiago Biachi De Castria, MD PHD
• Rafael W. Blanco, M. D.